

Index

A

- Adeno-associated virus (AAV), 24
- Adipose-derived mesenchymal stem cells (ADMSCs)
 - GFP-positive, 3–4, 6, 7
 - hindlimb ischemic mouse model, 8, 9
 - Ang-1*, 11
 - blood vessel site, 4
 - CD31*, 10, 11, 13–14
 - cell transplantation, 4
 - ephrin-B2*, 9, 11
 - ephrin-B4*, 11, 14
 - Flt-1*, *Flk-1* and *Ang-2*, 9, 10, 13
 - HGF*, 10, 11, 14
 - MMP-2*, 9, 11
 - Myf5*, 9, 11, 12, 14
 - MyoD*, 9, 11, 12, 14
 - PBS group, 6, 8
 - primer sequences, 5, 6
 - real-time quantitative reverse transcription PCR, 6
 - RNA extraction, 5
 - statistics, 6
 - TGF-β*, 10, 11, 14
 - transplanted cells, quantitation of, 5, 7, 10
 - VE-cadherin*, 10, 13
 - vWF*, 11, 14
- Adipose-derived stem cells (ADSCs)
 - characterization of, 149
 - data analysis, 148
 - diabetic mice
 - diabetic islets, damage stages of, 150, 152
 - glucose homeostasis of, 148, 150, 151
 - hematoxylin and eosin, 150, 152
 - islet size, 150, 152
 - survival of, 148, 150
 - histological and immunohistochemistry analyses, 147–148
 - insulin release, measurement of, 147
 - intravenous injection of, 152
 - specific MSC phenotype, 148
 - stem cell preparation, 146–147
 - stem cell transplantation, 147
 - streptozotocin (STZ)-induced diabetic mice, 147
 - transplantation, 153
- All-trans retinoic acid (ATRA), 69

Angiogenesis, 50

- ADMSCs, hindlimb ischemic mouse model (*see* Adipose-derived mesenchymal stem cells (ADMSCs))
 - definition, 3
 - molecular mechanisms, 3
- Anoikis, 12

B

- Basic fibroblast growth factor (bFGF), 3, 70, 72
- β-III-tubulin, 66, 67
- Bone marrow-derived MSCs (BM-MSCs), 48, 49, 111
 - on breast cancer cells, inhibitory effect
 - in vitro experiments, 117
 - in vivo experiments, 117
 - on breast cancer cells, stimulatory effect
 - in vitro experiments, 116
 - in vivo experiments, 117
 - glioma models, 52
 - interferon-β, 53
 - pro-tumor behavior of, 51
- Bone morphogenetic protein (BMP), 80

C

- Cancer stem cells (CSCs), 46, 47
 - identification of CSCs, HNSCCs (*see* Head and neck squamous cell carcinomas (HNSCCs))
 - strategies, 91
- Central tumor hypoxia, 98
- Cumulus cells (CCs), 83, 84
- Cumulus-oocyte complex (COC), 84

D

- Dental follicle stem cells (DFSCs), 66
- Dental pulp stem cells (DPSCs), 64–65
 - cryopreservation, 69
 - culture and expansion, 68–69
 - identification, 67
 - in vitro applications, neural tissue engineering
 - ATRA, 69
 - BDNF, 70–71
 - bFGF, 70
 - DMSO, 69
 - ECM, role of, 69–70

- Dental pulp stem cells (DPSCs) (*cont.*)
 NGF, 70
 PDGF-BB, 70
 regulation of differentiation, 69
 isolation, 67–68
 neural induction, protocols for
 culture medium, 71–72
 multistage culture, 71
 preinduction, 71
 surface coating, 71
 neural markers expression, 66–67
 source of multipotent cells, 66
- Dental stem cells (DSCs), 64, 65
 DFSCs, 66
 DPSCs (*see* Dental pulp stem cells (DPSCs))
 PDLSCs, 65
 SCAP, 65
 stem cells from human exfoliated deciduous teeth, 65
- Dimethyl sulfoxide (DMSO), 69
- E**
- Electron transport chain (ETC), 128–130
 Embryonic stem (ES) cells, 46, 47
 Engraftment, 30
 Ephrin receptor signalling pathway, 39, 40
 Epidermal growth factor (EGF), 72
 Esophageal squamous cell carcinoma (ESCC), 95
 Extracellular matrix (ECM), 69–70
- F**
- Fanconi anemia (FA)
 allogeneic HSCT, 21–22
 hematopoietic stem cells, sources of
 pluripotent stem cells, 24, 25
 umbilical cord blood, 24
 morbidity and mortality, 20
 pharmacological therapy, 20
 stem cell gene therapy
 AAV, 24
 CD34⁺ cells, 23
 clinical trials of, 23
 CRISPR/Cas9 system, 24
 FDA, 22
 “gene addition” approach, 23
 “gene correction” approach, 24
 international FA Gene Therapy Working Group, 23
 retroviral and lentiviral vectors, 23
 StemRegenin 1, 23
- Fibroblast growth factor receptor 3 (FGFR3), 80, 81
 Fluorescence-activated cell sorting (FACS), 91
 Foetal bovine serum (FBS)
 FBS-supplemented media, 31, 33, 35, 36
 pHs
 migration of SHED, 33, 37
 morphology of SHED, 33
 proliferation of SHED, 33
- G**
- Germ line stem cells (GSCs), 47
 Glucose tolerance test (GTT), 150, 151
 Glutathione S-transferase A4 (GSTA4), 137
 Graft-versus-host disease (GVHD), 21, 24
 Green fluorescent protein (GFP), 3–7
- H**
- Head and neck squamous cell carcinomas (HNSCCs)
 CSCs, 94, 99
 ABC transporters, 93
 ALDH, 96
 BMI1, 96
 CD24, 95–96
 CD44, 93–95
 CD133, 95
 clinical challenges of, 97–98
 Oct3/4, SOX2 and Nanog, 96–97
 side population discrimination assays,
 92–93
 sphere formation assays, 91–92
 xenografts, 97
 HPV, 90
 prognosis for, 90
 standard therapy for, 90
 traditional approaches, 91
- Hematopoietic stem cell transplantation (HSCT),
 21–22
- Hepatocyte growth factor (HGF), 3, 10, 11
 HNSCCs, *see* Head and neck squamous cell carcinomas
 (HNSCCs)
 Human adult germ stem cells (haGSCs), 82–83
 Human embryonic stem cells (hESCs), 79, 82, 83
 Human leukocyte antigens (HLA), 21
 Human MSCs (hMSCs)
 analysis of, 54
 cancer development and potential neoplastic
 transformation of, 51–52
 in cancer therapy, 52–53
 exogenous administration of, 54
 proliferation capacity of, 49–50
 use of, 55–56
- Human oocytes, 83–85
 Human papillomavirus (HPV), 90
 Human pluripotent stem cells (hPSCs), 79
 Human primordial germ cells (hPGCs), 79–80
 Human spermatogonial stem cells (hSSCs)
 BOLL and PRM2, 81
 features, 82
 FGFR3, 80, 81
 OCT4, 81
 UTF1, 80, 81
- Human telomerase reverse transcriptase (hTERT), 50
 Hydrogen peroxide (H₂O₂), 127, 131
 Hypoxia, 50
 Hypoxia-inducible factors (HIFs), 98
- I**
- Induced pluripotent stem (iPS) cells, 24, 25
 Inducible nitric oxide synthase (iNOS), 136
 Ingenuity Pathway Analysis (IPA), 33, 40
 International Society for Cellular Therapy (ISCT), 31, 49
- L**
- Lipoprotein lipase (LPL), 137

M

- MACSQuant[®], 32
 Major histocompatibility complex (MHC), 53
 MAP kinase phosphatase-1 (MKP-1), 136
 Mesenchymal stem cells (MSCs)
 ageing of, 40
 benefits of, 2
 in cancer development and therapeutic applications
 difficulties and limiting factors, 53–55
 hMSC (*see* Human MSCs (hMSCs))
 capability of, 3
 characteristics of, 47–48
 human adipose-derived stem cells, type 1 diabetic
 mellitus in mice (*see* Adipose-derived stem cells
 (ADSCs))
 incidental tumour-promoting effects of, 105
 in vitro expansion, 30
 isolation of, 48–49
 mechanisms, 2
 migratory and resident, 13
 migratory potential of, 105
 morphology and proliferation potential, 30
 motility and immunosuppressive properties, 31
 pre-angiogenic factors, 3
 SHED (*see* Stem cells from human extracted deciduous
 teeth (SHED))
 on tumour growth (*see* Tumour growth, MSCs)
 Microtubule-associated protein 2 (MAP2), 66
 Mitogen-activated protein kinases (MAPK), 94

N

- N*-acetylcysteine, 23
 NADPH oxidase (NOX), 128–131, 135, 136
 Nestin, 66, 67
 NeuN, 66
 Neuron-specific enolase (NSE), 71
 Nonesterified fatty acid (NEFA), 138

O

- Octamer-binding transcription factor 3/4 (Oct3/4), 96–97
 Oral squamous cell carcinoma (OSCC), 92, 93, 95, 96
 Oxidative stress, 135, 137, 138

P

- Periodontal ligament stem cells (PDLSCs), 65
 Phosphate buffer saline (PBS), 4, 6, 8–11, 14
 Polycystic ovary syndrome (PCOS), 83, 84
 Pooled human serum (pHS)
 and effect of FBS
 migration of SHED, 33
 morphology of SHED, 33
 proliferation of SHED, 33
 paracrine factors, 37, 39
 pHS-supplemented media, 31, 34, 35
 preparation of, 32
 Population doubling (PD), 33, 50
 Primordial germ cells (PGCs), 79–80

Q

- Quantitative real-time polymerase chain reaction
 (qRT-PCR), 79, 81

R

- Reactive oxygen species (ROS), 127
 in adipocyte differentiation, 130, 132
 adipose-derived stromal cells, 132–134
 role of ROS, 134–137
 scavengers, adipocytes and adipogenesis,
 137–138
 clinical implications, 138–139
 definition, 127
 redox biology, brief history of, 127–128
 sources and mechanism of production
 mitochondria, 129–131
 NADPH oxidase, 129–131
 Regenerative medicine, 64, 72
 Rheumatoid arthritis (RA), 53
 ROS, *see* Reactive oxygen species (ROS)

S

- Severe combined immunodeficiency (SCID), 107
 Sex-determining region Y-box2 (SOX2), 96–97
 Side population (SP), 92, 93
 Single-cell expression profiling and proteomics,
 78–79
 haGSCs, 82–83
 hPGCs, 79–80
 hSSCs, 80–82
 human oocytes, 83–85
 Single-cell RNA sequencing (scRNA-seq), 78, 80
 Somatic stem cells, 47
 Stem cell-mediated cancer therapy, hMSCs, *see* Human
 MSCs (hMSCs)
 Stem cells
 CSCs, 46, 47
 DSCs (*see* Dental stem cells (DSCs))
 embryonic, 46, 47
 GSCs, 47
 somatic, 47
 Stem cells from apical papilla (SCAP), 65
 Stem cells from human extracted deciduous teeth (SHED)
 data analysis, 33
 in vitro maintenance of, 32–33
 isolation and expansion of, 31
 molecular network analysis, 33
 MSC
 characteristics of, 34, 35
 identification of, 31–32
 paracrine factor, 33, 34, 37, 38
 pHS
 and effect of FBS, 33
 homogeneity, flat cell, 35
 migration of SHED, 37
 pHS-SM, 34–36
 preparation of, 32
 sample collection procedure, 31
 Stromal vascular fraction (SVF), 147
 Superoxide dismutase (SOD), 128

T

- Tissue culture-treated polystyrene (TCPS), 71
 TrypLE[™] Express, 32
 Tumor-associated fibroblasts (TAFs), 48

- Tumor necrosis factor alpha (TNF α), 135
- Tumour growth, MSCs, 108–109
- AD-MSc, inhibitory effect
 - in vitro experiments, 120
 - in vivo experiments, 120
 - AD-MSc, stimulatory effect
 - in vitro experiments, 119
 - in vivo experiments, 119
 - BM-MSCs on breast cancer cells
 - in vitro experiments, 116, 117
 - in vivo experiments, 117
 - cancer induction and MSC administration in vivo, 113–114
 - cancer sources and types, 112–113
 - exclusion criteria, 106
 - experimental factors, 115
 - in experimental studies, 112
 - inclusion criteria, 106
 - inhibition vs. stimulation, 107
 - in vivo and in vitro experiments, 110–111
 - in vivo specific factors, role of
 - experimental animal models, species in, 110
 - experimental animals, immune status of, 107, 109, 110
 - experimental model/design, 110
 - methods of exposure, 114
 - types of experiment, 107, 109
 - UC-MSCs, inhibitory effect
 - in vitro experiments, 118
 - in vivo experiments, 118
 - UC-MSCs, stimulatory effect
 - in vitro experiments, 117
 - in vivo experiments, 117
- Tyrosine hydroxylase, 66
- U**
- Undifferentiated embryonic cell transcription factor 1 (UTF1), 80, 81
- V**
- Vascular endothelial growth factor (VEGF), 3